Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Benjamin Levy, MD
Progress in Breast Cancer Care: Translating SABCS Data Into Practice
Charles E. Geyer Jr., MD, FACP
Komal Jhaveri, MD, FACP
Addressing Unmet Needs in Metastatic Uveal Melanoma
Marlana Orloff, MD
Gregory Daniels, MD, PhD
Jesse Keller, MD
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
A.J. Gelderblom, MD, PhD
All Sides of the Joint: Integrated TGCT Care Across Specialties
Michiel van de Sande, MD, PhD
Chelsea Cole, MD
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
Giuseppe Curigliano, MD, PhD
From Data to Debate: Global Perspectives on HR+/HER2- mBC Care
Cynthia Villarreal-Garza, MD, DSc
Hiraji Iwata, MD, PhD
Routes Reconsidered: A Case-Based Debate in SERD Selection
Spotlight on Europe: Adapting the Evidence
Spotlight on Asia-Pacific: Practice Beyond Borders
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Kathleen Moore, MD, MS
MOA: CDH6-Targeted Antibody-Drug Conjugates
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Joyce F. Liu, MD, MPH
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.